ArticlePloS one2013
Specific transfection of inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseases.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 141 citations in OpenAlex.
- Metabolic Tagging Technology of Exosomes-An Updated Review.Current pharmaceutical design · 2025Review
- Plant-derived Exosomes: Pioneering Breakthroughs in Therapeutics, Targeted Drug Delivery, and Regenerative Medicine.Pharmaceutical nanotechnology · 2025Review
- Immune cells: potential carriers or agents for drug delivery to the central nervous system.Military Medical Research · 2024Review
- Exosome-Mediated Antigen Delivery: Unveiling Novel Strategies in Viral Infection Control and Vaccine Design.Vaccines · 2024Review
- Exosomes-mediated drug delivery for the treatment of myocardial injury.Annals of medicine and surgery (2012) · 2024Review
- Correction: Specific transfection of inflamed brain by macrophages: A new therapeutic strategy for neurodegenerative diseases.PloS one · 2024Article
- Retraction: Specific Transfection of Inflamed Brain by Macrophages: A New Therapeutic Strategy for Neurodegenerative Diseases.PloS one · 2024Article
- Unlocking the potential of exosomes: a breakthrough in the theranosis of degenerative orthopaedic diseases.Frontiers in bioengineering and biotechnology · 2024Review
- Novel Therapeutic Mechanisms and Strategies for Intracerebral Hemorrhage: Focusing on Exosomes.International journal of nanomedicine · 2024Review
- Macrophage-based delivery of anti-fibrotic proteins alleviates bleomycin-induced pulmonary fibrosis in mice.Bioengineering & translational medicine · 2023Article
- Strategies for Engineering of Extracellular Vesicles.International journal of molecular sciences · 2023Review
- An update in the applications of exosomes in cancer theranostics: from research to clinical trials.Journal of cancer research and clinical oncology · 2023Review
- Targeted Nanocarriers Co-Opting Pulmonary Intravascular Leukocytes for Drug Delivery to the Injured Brain.ACS nano · 2023Article
- Liquid Biopsy at the Frontier of Kidney Diseases: Application of Exosomes in Diagnostics and Therapeutics.Genes · 2023Review
- Exosomes as an Emerging Plasmid Delivery Vehicle for Gene Therapy.Pharmaceutics · 2023Review
- Extracellular Vesicles as Therapeutic Resources in the Clinical Environment.International journal of molecular sciences · 2023Review
- Current Knowledge and Future Perspectives of Exosomes as Nanocarriers in Diagnosis and Treatment of Diseases.International journal of nanomedicine · 2023Review
- Mannosylated Systems for Targeted Delivery of Antibacterial Drugs to Activated Macrophages.International journal of molecular sciences · 2022Article
- Small Extracellular Vesicles Secreted by Nigrostriatal Astrocytes Rescue Cell Death and Preserve Mitochondrial Function in Parkinson's Disease.Advanced healthcare materials · 2022Article
- Sequestration of Inflammation in Parkinson's Disease via Stem Cell Therapy.International journal of molecular sciences · 2022Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
- Correction · 2024-07-02Concerns/Issues about Image · Concerns/Issues about Article · Error in Image ·
- Retraction · 2024-12-17Concerns/Issues about Data · Concerns/Issues about Image · Concerns/Issues about Results and/or Conclusions · Falsification/Fabrication of Data · Unreliable Results and/or Conclusions · Upgrade/Update of Prior Notice(s) · · Matthew J Haney 1 , Yuling Zhao, Emily B Harrison, Vivek Mahajan, Shaheen Ahmed, Zhijian He, Poornima Suresh, Shawn D Hingtgen, Natalia L Klyachko, R Lee Mosley, Howard E Gendelman, Alexander V Kabanov, Elena V Batrakova
- Erratum issued
- Retracted
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
Abstract
The ability to precisely upregulate genes in inflamed brain holds great therapeutic promise. Here we report a novel class of vectors, genetically modified macrophages that carry reporter and therapeutic genes to neural cells. Systemic administration of macrophages transfected ex vivo with a plasmid DNA (pDNA) encoding a potent antioxidant enzyme, catalase, produced month-long expression levels of catalase in the brain resulting in three-fold reductions in inflammation and complete neuroprotection in mouse models of Parkinson's disease (PD). This resulted in significant improvements in motor functions in PD mice. Mechanistic studies revealed that transfected macrophages secreted extracellular vesicles, exosomes, packed with catalase genetic material, pDNA and mRNA, active catalase, and NF-κb, a transcription factor involved in the encoded gene expression. Exosomes efficiently transfer their contents to contiguous neurons resulting in de novo protein synthesis in target cells. Thus, genetically modified macrophages serve as a highly efficient system for reproduction, packaging, and targeted gene and drug delivery to treat inflammatory and neurodegenerative disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.